Pricing and Reimbursement - OHE - Page 2

We found for

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Read more

© Mayer Tawfik/Unsplash

Insight
December 2021

OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates

CBO Report

Insight
September 2021

Does the New CBO Report Change Anything?

blog-4-quote-1-002-v2

Insight
September 2021

Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking

blog-3-graph-1_smaller

Insight
September 2021

CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation

Blog-2-quote-2-small

Insight
September 2021

The CBO Doesn’t Understand Investors

test-image-5

Insight
September 2021

H.R. 3 is the Wrong Policy for the Wrong Problem

Insight
September 2021

OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare

Insight
May 2021

Would Waiving COVID-19 Vaccines Patents Save Lives?

Key-Learnings-small

Insight
April 2021

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

Insight
March 2021

Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System

Insight
March 2021

Time to Tackle the Challenges around Combination Therapies for Cancer

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations

Read more

© Rawpixel.com

It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?

Read more

Payment Models for Multi-Indication Therapies

Read more

© Photology1971/Shutterstock

Insight
January 2021

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments

01
02
03
04
05
06
00